<p>在當前市場交易中，<strong>再生元製藥公司 (NASDAQ: REGN)</strong> 的股價為 $780.00，下降幅度為 <strong>0.95%</strong>。然而，在過去一個月中，該公司的股價上漲了 <strong>1.61%</strong>，在過去一年中上漲了 <strong>12.75%</strong>。股東可能會想知道該股票是否被高估，即使公司在當前交易中的表現不盡如人意。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="過去一年圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png"/></p>
<h3>比較再生元製藥的市盈率與同行</h3>
<p>市盈率是長期股東用來評估公司市場表現的指標，通常與整體市場數據、歷史收益和行業整體情況進行比較。較低的市盈率可能表明股東不期望該股票在未來表現更好，或者可能意味着公司被低估。</p>
<p>與生物技術行業的整體市盈率 <strong>76.09</strong> 相比，再生元製藥公司的市盈率為 <strong>18.48</strong>，較低。股東可能傾向於認為該股票的表現可能不如行業同行。也有可能該股票被低估。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="儀表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png"/></p>
<p>總之，市盈率是分析公司市場表現的有用指標，但它也有其侷限性。雖然較低的市盈率可能表明公司被低估，但它也可能暗示股東不期望未來增長。此外，市盈率不應單獨使用，因為行業趨勢和商業週期等其他因素也會影響公司的股價。因此，投資者應將市盈率與其他財務指標和定性分析結合使用，以做出明智的投資決策。</p>

再生元制藥

動態生物技術與基因組 ETF - Invesco

IBBQ

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

<p>再生元製藥（Regeneron Pharmaceuticals Inc.，NASDAQ:REGN）股票目前價格為 780.00 美元，反映出下跌 0.95%。在過去一個月中，該股票上漲了 1.61%，在過去一年中上漲了 12.75%。公司的市盈率為 18.48，顯著低於生物技術行業平均水平 76.09，這表明可能存在被低估或較低的增長預期。建議投資者在做出明智決策時，考慮市盈率與其他財務指標和定性因素的結合</p>

<p>In the current market session, <strong>Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)</strong> stock price is at $780.00, after a <strong>0.95%</strong> drop. However, over the past month, the company's stock spiked by <strong>1.61%</strong>, and in the past year, by <strong>12.75%</strong>. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.</p>
<div class="lb-trans"><p>在當前市場交易中，<strong>再生元製藥公司 (NASDAQ: REGN)</strong> 的股價為 $780.00，下降幅度為 <strong>0.95%</strong>。然而，在過去一個月中，該公司的股價上漲了 <strong>1.61%</strong>，在過去一年中上漲了 <strong>12.75%</strong>。股東可能會想知道該股票是否被高估，即使公司在當前交易中的表現不盡如人意。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png" alt="Past Year Chart" original-src="https://www.benzinga.com/files/images/story/2026/1772661628_0.png"/></p>
<h3>Comparing Regeneron Pharmaceuticals P/E Against Its Peers</h3>
<div class="lb-trans"><h3>比較再生元製藥的市盈率與同行</h3>
</div><p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued.</p>
<div class="lb-trans"><p>市盈率是長期股東用來評估公司市場表現的指標，通常與整體市場數據、歷史收益和行業整體情況進行比較。較低的市盈率可能表明股東不期望該股票在未來表現更好，或者可能意味着公司被低估。</p>
</div><p>Compared to the aggregate P/E ratio of the <strong>76.09</strong> in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower P/E ratio of <strong>18.48</strong>. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued.</p>
<div class="lb-trans"><p>與生物技術行業的整體市盈率 <strong>76.09</strong> 相比，再生元製藥公司的市盈率為 <strong>18.48</strong>，較低。股東可能傾向於認為該股票的表現可能不如行業同行。也有可能該股票被低估。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png" alt="Guage" original-src="https://www.benzinga.com/files/images/story/2026/1772661628_1.png"/></p>
<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.</p>
<div class="lb-trans"><p>總之，市盈率是分析公司市場表現的有用指標，但它也有其侷限性。雖然較低的市盈率可能表明公司被低估，但它也可能暗示股東不期望未來增長。此外，市盈率不應單獨使用，因為行業趨勢和商業週期等其他因素也會影響公司的股價。因此，投資者應將市盈率與其他財務指標和定性分析結合使用，以做出明智的投資決策。</p>
</div>

P/E Ratio Insights for Regeneron Pharmaceuticals

benzinga_article

Invesco Nasdaq Biotechnology ETF

再生元製藥市盈率的深入分析